[Direct drug delivery to the brain]
- PMID: 17002024
[Direct drug delivery to the brain]
Abstract
The authors of the review discuss the present-day state of and promising approaches to directed delivery of biological agents into the brain. Special attention is drawn to micellar and liposomal transport through the blood-brain barrier (BBB) targeted by immunochemical vectors, such as native or hydrophobized antibodies to specific antigens located at the BBB or in the brain parenchyma.
Similar articles
-
Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." The blood-brain barrier: a physical and conceptual challenge.Alzheimers Dement. 2009 Sep;5(5):435-6. doi: 10.1016/j.jalz.2009.07.002. Alzheimers Dement. 2009. PMID: 19751924 No abstract available.
-
Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.Alzheimers Dement. 2009 Sep;5(5):437-8. doi: 10.1016/j.jalz.2009.07.037. Alzheimers Dement. 2009. PMID: 19751925 No abstract available.
-
Nanoparticle technology for drug delivery across the blood-brain barrier.Drug Dev Ind Pharm. 2002 Jan;28(1):1-13. doi: 10.1081/ddc-120001481. Drug Dev Ind Pharm. 2002. PMID: 11858519 Review.
-
Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.Med Res Rev. 2013 May;33(3):457-516. doi: 10.1002/med.21252. Epub 2012 Mar 20. Med Res Rev. 2013. PMID: 22434495 Review.
-
Drug targeting to the brain.Annu Rev Pharmacol Toxicol. 2007;47:323-55. doi: 10.1146/annurev.pharmtox.47.120505.105237. Annu Rev Pharmacol Toxicol. 2007. PMID: 16961459 Review.
Cited by
-
Enhanced brain penetration of hexamethonium in complexes with derivatives of fullerene C60.Dokl Biochem Biophys. 2016 May;468(1):173-5. doi: 10.1134/S1607672916030030. Epub 2016 Jul 15. Dokl Biochem Biophys. 2016. PMID: 27417712